Retatrutide LY3437943: What Every Researcher Needs to Know
The designation LY3437943 doesn't get as much attention as the common name Retatrutide, but both refer to the same compound: the first triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly. Understanding Retatrutide under both of these identifiers matters because the published research literature uses both interchangeably, and researchers who aren't aware of that can...
0 Comments
0 Shares
